Drl

Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up

With increased US competition from FY26, DRL plans portfolio shifts, inorganic growth, cost control and global expansion to manage profit and revenue impact

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

Stocks to watch, July 19: Infosys, RIL, Vi, LTTS, Tata Consumer, DRL, CEAT

At 6:36 AM, GIFT Nifty futures were up 19 points, trading at 24,828.50 levels, indicating a higher start for the day.

Dr Reddy's Laboratories Q4 PAT grows nine-fold riding on US, India biz

For the full year 2022-23, DRL's revenues were up 15 percent to Rs 24,587.9 crore while the PAT grew by 91 percent to Rs 4,506.7 crore

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday

Valuations turning attractive for Dr Reddy's as company outperforms sector

US price erosion, India growth trends would be keenly tracked

DRL plans to start paediatric trials of Sputnik Light vaccine soon

Booster shot with Sputnik trials may also begin

Three trading ideas by Ajit Mishra: Buy Adani Ports, Federal Bank; sell DRL

We're seeing noticeable traction in the banking pack and Federal Bank has recently witnessed a breakout from a consolidation range

Stocks to watch: DRL, TVS Motor, PSP Projects, EID Parry India, Voda Idea

The recovery officer of Debt Recovery Tribunal (DRT) on Tuesday offloaded shares worth Rs 50 lakh of McDowell Holdings Ltd through an open market transaction

Stocks to watch: RIL, ICICI Lombard, PNB, DRL, Barbeque Nation, NTPC, HFCL

JSPL expects to conclude the deal to sell its 96.42 per cent stake in its arm Jindal Power for Rs 7,401 crore to a promoters-owned firm Worldone by this year end

Ceat, Dr Reddy's: Be careful! These 5 stocks can dip up to 15% from here

A clear breakdown on price action and chart patterns may lead to slide in these stocks

Stocks to watch: Nazara Tech, DRL, Adani Transmission, JSW Steel, Biocon

Pharma major Dr Reddy's Laboratories (DRL) expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Stocks to watch: GAIL, Tata Motors, Dishman Carbogen, DRL, Karnataka Bank

Jaguar Land Rover's retail sales fell 9 per cent YoY to 1,28,469 units in the October-December quarter

DRL launches Avigan for mild Covid-19 infections at Rs 99 a tablet

Drug to be imported from Japan for time being, India manufacturing to start soon

DRL, Japan's Eisai ink licensing pact for anticancer agent

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets